PMS-PIOGLITAZONE TABLET
Land: Kanada
Tungumál: enska
Heimild: Health Canada
Vara einkenni
(SPC)
14-05-2018
Sum skjöl fyrir þessa vöru eru ekki tiltæk eins og er, þú getur sent beiðni til þjónustu við viðskiptavini okkar og við munum láta þig vita um leið og við getum fengið þau.
Senda beiðni.
Senda beiðni.
Virkt innihaldsefni:
PIOGLITAZONE (PIOGLITAZONE HYDROCHLORIDE)
Fáanlegur frá:
PHARMASCIENCE INC
ATC númer:
A10BG03
INN (Alþjóðlegt nafn):
PIOGLITAZONE
Skammtar:
30MG
Lyfjaform:
TABLET
Samsetning:
PIOGLITAZONE (PIOGLITAZONE HYDROCHLORIDE) 30MG
Stjórnsýsluleið:
ORAL
Einingar í pakka:
100
Gerð lyfseðils:
Prescription
Lækningarsvæði:
THIAZOLIDINEDIONES
Vörulýsing:
Active ingredient group (AIG) number: 0141541002; AHFS:
Leyfisstaða:
APPROVED
Leyfisdagur:
2007-12-05
Vara einkenni
PRODUCT MONOGRAPH
PR
PMS-PIOGLITAZONE
Pioglitazone Hydrochloride Tablets
15 mg, 30 mg, 45 mg
USP
Anti-Diabetic Agent
PHARMASCIENCE INC.
6111 Royalmount Ave., Suite 100
Montréal, Québec
H4P 2T4
Date of Revision:
May 14, 2018
www.pharmascience.com
Submission Control No: 215147
_pms-PIOGLITAZONE Product Monograph _
_Page 2 of 46_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................... 3
SUMMARY PRODUCT INFORMATION
...............................................................................
3
INDICATIONS AND CLINICAL USE
.....................................................................................
3
CONTRAINDICATIONS
..........................................................................................................
4
WARNINGS AND PRECAUTIONS
.........................................................................................
4
ADVERSE REACTIONS
...........................................................................................................
9
DRUG INTERACTIONS
.........................................................................................................
13
DOSAGE AND ADMINISTRATION
.....................................................................................
15
OVERDOSAGE
.......................................................................................................................
16
ACTION AND CLINICAL PHARMACOLOGY
................................................................... 17
STORAGE AND STABILITY
.................................................................................................
23
DOSAGE FORMS, COMPOSITION AND PACKAGING
.................................................... 23
PART II: SCIENTIFIC INFORMATION
...............................................................................
24
PHARMACEUTICAL INFORMATION
.................................................................................
24
CLINICAL TRIALS
..........................................................
Lestu allt skjalið
